Half-Life of Heparin
The plasma half-life of unfractionated heparin (UFH) is dose-dependent and ranges from 0.5 to 2 hours, while low-molecular-weight heparin (LMWH) has a significantly longer half-life of approximately 3 to 4 hours.
Unfractionated Heparin (UFH)
UFH exhibits biphasic clearance kinetics that make its half-life dose-dependent 1:
- Rapid saturable clearance: Zero-order process involving binding to proteins, endothelial cells, and macrophages
- Slower first-order elimination: Primarily renal clearance
The plasma half-life ranges from 0.5 to 2 hours depending on the dose administered 1. At therapeutic doses, a considerable proportion is cleared through the rapid saturable mechanism, making the anticoagulant response nonlinear—both intensity and duration of effect rise disproportionately with increasing doses 2.
Key Clinical Implications for UFH:
- The saturable clearance mechanism contributes to the variable and unpredictable anticoagulant response seen among patients 2
- Binding to plasma proteins (antithrombin, fibrinogens, globulins, serum proteases, lipoproteins) reduces bioavailability and contributes to heparin resistance 2, 1
- Clearance is primarily through liver and reticuloendothelial cells, with secondary renal elimination 1
Low-Molecular-Weight Heparin (LMWH)
LMWH has superior pharmacokinetic properties compared to UFH 2:
- Plasma half-life: 3 to 4 hours for anti-Xa activity 3, 4
- Anti-IIa activity half-life is shorter and similar to UFH 3
- Near-complete subcutaneous absorption (bioavailability ≥90%) 5
- Linear, dose-proportional pharmacokinetics 2, 5
Why LMWH Has a Longer Half-Life:
The extended half-life results from reduced binding to plasma proteins, endothelial cells, and macrophages due to the smaller molecular size (mean molecular weight 4,500-5,000 Da vs. 15,000 Da for UFH) 2. This reduced non-specific binding translates to:
- More predictable dose-response relationship
- Better bioavailability at low doses
- Ability to use fixed, weight-based dosing without monitoring 2
LMWH Clearance:
Primarily renal elimination 2—a critical distinction from UFH. This means:
- Biological half-life is prolonged in renal failure patients 2
- Dose adjustments required when creatinine clearance <30 mL/min
- Less affected by the saturable cellular mechanisms that complicate UFH kinetics
Clinical Pitfalls to Avoid:
Do not assume LMWH agents are interchangeable—different preparations (enoxaparin, dalteparin, tinzaparin) have varying pharmacokinetic properties due to different depolymerization methods 2, 5
Adjust LMWH dosing in severe renal impairment (CrCl <15-30 mL/min) since renal clearance predominates 2, 5
Elderly patients (>60 years) may have higher UFH plasma levels and prolonged aPTTs at similar doses compared to younger patients 1
UFH's dose-dependent half-life means that simply increasing the dose does not produce proportional increases in anticoagulant effect—the response is nonlinear 2, 1